// App-Quantinova.ai

840TiP : Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study

Researchers

Presenter

  • U.Emmenegger

Principal Investigators

  • S.Cheng

  • K.Zukotynski

  • P.Cheung

Medical Centers

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

  • Medicine and Radiology, McMaster University, Hamilton, ON, Canada

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating DNA

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved